The point mutation 1849 (G→T) Janus kinase 2 (JAK2) is a member of a group of cytoplasmic tyrosine kinases are that involved in the transduction of signals from growth factor receptors. 1 JAK2 is a key player in the JAK-signal transducer and activator of transcription (STAT) pathway. On autophosphorylation following activation via ligand binding, JAK2 recruits STAT molecules, which are then phosphorylated and translocate to the nucleus to act as transcription factors. 1 It has been recently reported that a somatic point mutation, 1849 (G→T), in the JAK2 gene causing phenylalanine to be substituted for valine in codon 617 (V617F) is present in a number of myeloproliferative disorders such as polycythemia vera (PRV [65%-93%]), essential thrombocythemia (ET [23%-57%]), idiopathic myelofibrosis (IMF [43%-53%]), and, to a smaller extent (~5%), chronic myelomonocytic leukemia, myelodysplastic syndrome, systemic mastocytosis, and chronic neutrophilic leukemia. [2] [3] [4] [5] [6] [7] [8] This mutation disrupts the autoinhibitory J H 2 domain of JAK2, 9 which leads to the constitutive activation of JAK2 and, subsequently, uncontrolled proliferation. 2 No other mutations in JAK2 have been detected, a consistent finding across the 4 independent groups who initially described the V617F mutation. [2] [3] [4] [5] 
A b s t r a c t

The point mutation 1849 (G→T) V617F in the JAK2 gene occurs at high frequency in several chronic myeloproliferative diseases. Although a number of V617F mutation detection methods have been described, few are readily implemented in a diagnostic setting. We developed a simple and sensitive allelespecific competitive blocker polymerase chain reaction (ACB-PCR) assay to detect the V617F mutation. DNA was extracted from peripheral whole blood samples of 26 patients with chronic myeloproliferative disease. The ACB-PCR limit of detection was 1%. All positive samples detected by sequencing were detected by ACB-PCR. In 3 patients with essential thrombocythemia, the V617F mutation was readily detected by ACB-PCR but was near the detection limit of sequencing, confirming that ACB-PCR is more effective at detecting V617F when the mutant cell population is low. Detection of the monomorphic JAK2 V617F mutation using the ACB-PCR assay is easy to perform, rapid, sensitive, and cost-effective, which are key features of an ideal diagnostic method.
Janus kinase 2 (JAK2) is a member of a group of cytoplasmic tyrosine kinases are that involved in the transduction of signals from growth factor receptors. 1 JAK2 is a key player in the JAK-signal transducer and activator of transcription (STAT) pathway. On autophosphorylation following activation via ligand binding, JAK2 recruits STAT molecules, which are then phosphorylated and translocate to the nucleus to act as transcription factors. 1 It has been recently reported that a somatic point mutation, 1849 (G→T), in the JAK2 gene causing phenylalanine to be substituted for valine in codon 617 (V617F) is present in a number of myeloproliferative disorders such as polycythemia vera (PRV [65%-93%]), essential thrombocythemia (ET [23%-57%]), idiopathic myelofibrosis (IMF [43%-53%]), and, to a smaller extent (~5%), chronic myelomonocytic leukemia, myelodysplastic syndrome, systemic mastocytosis, and chronic neutrophilic leukemia. [2] [3] [4] [5] [6] [7] [8] This mutation disrupts the autoinhibitory J H 2 domain of JAK2, 9 which leads to the constitutive activation of JAK2 and, subsequently, uncontrolled proliferation. 2 No other mutations in JAK2 have been detected, a consistent finding across the 4 independent groups who initially described the V617F mutation. [2] [3] [4] [5] The incidence of the V617F mutation in patients with bcr-abl-myeloproliferative disorders varies, but defining the presence or absence of this mutation is now part of clinical diagnostic algorithms, 10 and, in the future, will be part of the assessment for treatment with the potential introduction of JAK2 inhibitors.
Several groups have developed assays to enable detection of the V617F mutation (recently reviewed by Greiner 11 ). Some of these methods have been inappropriate for a routine diagnostic laboratory because they are comparatively labor-intensive methods with low detection sensitivities, eg, restriction enzyme (BsaXI) digestion following polymerase chain reaction (PCR) 12, 13 or sequencing. [2] [3] [4] [5] Other methods are relatively complex, such as those approaches with a pyrosequencer, 7, 8 fluorescence probes, [14] [15] [16] or denaturing high-performance liquid chromatography, 17 considering the monomorphic nature of the V617F mutation.
We developed a diagnostic allele-specific competitive blocker (ACB)-PCR assay to identify the V617F mutation. The sensitivity of the assay allows it to be performed on peripheral whole blood DNA without the need to separate the granulocytes. The ACB-PCR assay is quick, easy, and costeffective. In addition, it is highly sensitive, permitting detection of the mutation in patients with low mutant cell levels.
Materials and Methods
Samples
The peripheral blood samples of 26 patients with myeloproliferative disease (PRV, 8; ET, 15; IMF, 2; postpolycythemic myelofibrosis and myeloid metaplasia, 1) and 4 patients with lymphoproliferative disease were analyzed by the Pathology Department, the Peter MacCallum Cancer Centre, East Melbourne, Australia. The patients were undergoing studies for hematologic disease. Normal peripheral blood samples were obtained from 16 healthy volunteers. All samples were collected into tubes containing EDTA and were obtained in accordance with the Peter MacCallum Cancer Centre Ethics of Human Research guidelines.
DNA Extraction
DNA was isolated from the peripheral blood samples using the Wizard Genomic DNA Purification Kit (Promega, Madison, WI) according to the manufacturer's instructions.
ACB Assay
Approximately 100 ng of DNA was amplified in a total volume of 25 µL containing 200 nmol/L of Normal_f primer 5'-GCATTTGGTTTTAAATTATGGAGTATGTG-phosphate (a phosphate group was added to the 3' end to prevent extension from the normal primer, blocking amplification of the normal allele), 400 nmol/L each of Mutant_f primer 5'-GCATTTGGTTTTAAATTATGGAGTATGAT and reverse primer 5'-ACTGACACCTAGCTGTGATCCTG, 2 mmol/L of magnesium chloride, 50 µmol/L of each deoxynucleotide triphosphate (dNTP), 0.5 U of HotStar Taq (Qiagen, Hilden, Germany), and 1× buffer (Qiagen). All primers were purchased from Sigma Aldrich (Castle Hill, Australia). The cycling conditions were 95°C (15 minutes) and 45 cycles of 94°C (30 seconds), 64°C (30 seconds), 72°C (30 seconds), and a final 72°C extension for 10 minutes. The 139-base-pair products were visualized on a 2% ethidium bromide-stained agarose gel. The presence of a band indicated that the sample was positive for the V617F mutation. All samples were first amplified using the control PCR reaction of JAK2 (see the next section). Each sample was set up in triplicate in the ACB-PCR assay to ensure that no false-negative results were obtained, and at least 3 negative control samples were run alongside the test samples to exclude false-positive results.
Control Reaction PCR of JAK2
A control PCR reaction that amplifies exon 14 of JAK2 was performed for all samples to exclude false-negative results in case the extracted DNA samples were not of adequate quality to amplify. The amplification was performed as described for the ACB-PCR assay except the primers Control_f 5'-TTCCTTAGTCTTTCTTTGAAGCAG and Control_r 5'-ACTGACACCTAGCTGTGATCCTG were used with 200 µmol/L of dNTPs. The 191-base-pair products were visualized on a 2% ethidium bromide-stained agarose gel.
Direct Sequencing
To validate the ACB-PCR assay, each sample was analyzed by direct sequencing of the control reaction PCR products (exon 12, JAK2) using a standard fluorescent dye method. Briefly, products were incubated with EXO-SAP-IT (USB, Cleveland, OH), following the manufacturer's instructions. The enzymatically cleaned PCR products were used as a template for the cycle sequencing reaction. Forward and reverse sequencing were performed using Big Dye Terminator version 3.1 chemistry (Applied Biosystems, Foster City, CA) according to the manufacturer's instructions. After cycle sequencing was completed, products were ethanol precipitated and, after addition of Hi-Di (Applied Biosystems), analyzed on an ABI 3100 (Applied Biosystems).
Results
Optimization
The important variables for the ACB-PCR assay to detect the V617F mutation were the annealing temperature, dNTP concentration, and primer concentration. The majority of the conditions were modeled from a previous ACB-PCR assay. 18 Annealing temperatures of 60°C, 62°C, 64°C, and 68°C were initially used with a low concentration of 50 µmol/L of dNTPs to test the specificity of the primers. A low concentration of dNTPs encourages the correct base to be incorporated during the PCR reaction, increasing fidelity and accuracy at the critical 3' end of the primers. In addition, it was previously found that the ideal primer concentration was when the mutant primer and normal primer (with the 3' phosphate blocking group) were used at a 2:1 ratio. The conditions were deemed optimal when repeated negative control DNA samples did not amplify while the positive patient samples were robustly amplified. These conditions are those described in the "Materials and Methods" section. If the ACB-PCR assay is performed under nonoptimal conditions, mispriming may occur from the normal primer and amplification would be observed in the negative control samples.
Detection Sensitivity
The sensitivity of the ACB-PCR assay was assessed using serial dilutions of the HEL cell line DNA (which carries the V617F mutation) with DNA of normal control peripheral blood samples ❚Image 1A❚. Amplification products were visible to the level of 1%. This level of sensitivity is higher than that of sequencing (10%-40%), 2-5 pyrosequencing (5%-10%), 7, 8 and melt curve analysis (1%-10%). [14] [15] [16] Furthermore, peripheral whole blood extraction using a commercial kit further simplified the assay because extra steps to isolate granulocytes for low-level disease detection were unnecessary owing to the high sensitivity of the ACB-PCR assay.
Patient Samples
Samples from 26 patients with myeloproliferative disease were analyzed using the ACB-PCR assay ❚Image 1B❚, and the results were correlated with the sequencing results ❚Table 1❚. All ACB-PCR results were concordant with the direct sequencing results. However, analysis of the sequencing chromatograms of 3 patients with ET revealed that in 2 patients, the mutation could not be distinguished from the background and in 1 patient, the mutation was observed but at the limit of detection. No amplification occurred in the ACB-PCR assays of samples from the 16 healthy subjects and 4 patients with lymphoproliferative diseases. N 6 ) , an NTC and a V617F+ patient control sample (+). The M is pUC19/HpaII. Amplified samples T 3 -T 6 were positive by the ACB-PCR assay and were confirmed V617F+ by direct sequencing. Samples T 1 , T 2 , and T 7 -T 10 were negative by the ACB-PCR assay and also confirmed negative by direct sequencing.
Discussion
The ACB-PCR (first described by Orou et al 19 ) is based on the amplification refractory mutation system method 20 in which relevant alleles are targeted using specific primers. Allele-specific assays such as the amplification refractory mutation system are efficient techniques for the detection of monomorphic mutations because they are simple and easy to perform. However, standard allele-specific assays can be prone to mispriming. 12, 21, 22 Therefore, we chose to adopt an ACB-PCR assay to detect the V617F JAK2 mutation. In an ACB-PCR assay, 3 primers are combined in a single tube, a forward primer with a modified 3' end, a second forward primer that targets the mutant allele, and a reverse primer. Under optimized conditions, only the mutant allele (the allele of interest) is amplified, and owing to the 3' modification of the normal primer, amplification of the normal allele is inhibited.
Theoretically, any blocking group can be incorporated at the 3' end of the normal primer to prevent amplification, ie, a dideoxynucleotide. In this study, a phosphate group was selected because it was an inexpensive modification that was widely available from commercial oligonucleotide companies.
Similar to any PCR test, some optimization of the ACB-PCR assay was required but was minimal owing to the attachment of the 3' phosphate group on the normal primer. Under optimal routine conditions, the ACB-PCR assay was able to detect the V617F mutation at the level of 1% or approximately 1 mutant cell per 100 normal cells. This high level of detection sensitivity was equivalent to that of previous allelespecific assays. 18 The advantage of such a high detection level of the ACB-PCR assay was made apparent when studying a cohort of ET cases. In 3 ET cases, the V617F mutation would not have been detected by sequencing because the mutant peak was at the level of background on the chromatograms. Low levels of V617F in patients with ET may be due to heterogeneity in the granulocyte population, and the potential to miss the V617F mutation in some patients with ET using less sensitive techniques has been reported. 23, 24 We detected the JAK2 V617F mutation in 6 of 8 patients with PRV, 10 of 15 with ET, and 1 of 2 with IMF. The pattern of incidence in each of the disease states is consistent with previous reports. [2] [3] [4] [5] 7 The mutation was not present in the patient with postpolycythemic myelofibrosis and myeloid metaplasia.
The ACB-PCR assay described in this article has subsequently been implemented in the routine diagnostic laboratory of the Pathology Department, the Peter MacCallum Cancer Centre. Currently, the V617F mutation has been identified in 15 (83%) of 18 patients with PRV, 14 (56%) of 25 with ET, and 5 (71%) of 7 with IMF. The ACB-PCR assay is rapid and highly sensitive. It is a suitable technique for V617F mutation detection with wider appeal for routine diagnostic laboratories because it uses standard equipment, has few sample manipulation steps, and can be performed directly on DNA extracted from peripheral whole blood samples.
